Inovio Pharmaceuticals is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 170 total vaccine candidates in development (June 2020).[4][5]
InovioPharmaceuticals is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for...
to InovioPharmaceuticals' INO-3112 immunotherapy, currently in Phase I/II, under an agreement which could net more than US$727.5 million for Inovio. INO-3112...
for SARS-CoV-2, being: Moderna, InovioPharmaceuticals, and the University of Queensland (UQ). By February 2020, Inovio announced that it had produced...
as of 2009 and 2010 include Theraclone, VaxInnate, Crucell NV, InovioPharmaceuticals, Immune Targeting Systems (ITS) and iQur. In 2019, Distributed Bio...
began testing at the National Institutes of Health. Separately, InovioPharmaceuticals and GeneOne Life Science began tests of a different DNA vaccine...
PMID 26386540. "Inovio Begins Phase 3 Clinical Trial of VGX-3100 for the Treatment of HPV-Related Cervical Pre-Cancer". www.inovio.com. InovioPharmaceuticals. Archived...
likely not be sufficient to eradicate HCV completely. As of 2020, InovioPharmaceuticals is developing a synthetic multi-antigen DNA vaccine covering HCV...
COVID-19. Some of its competitors were companies such as Novavax, InovioPharmaceuticals, and Moderna. In February 2020, Vaxart began a program to develop...
GlaxoSmithKline Gyeongbuk Institute for Bio Industry Incepta PharmaceuticalsInovioPharmaceuticals Instituto Butantan Merck Pfizer Sanofi Shantha Biotechnics...
involve up to 120 subjects aged between 18 and 35. Separately, InovioPharmaceuticals and GeneOne Life Science began tests of a different DNA vaccine...
government research funding were: Indirectly funded companies include: Inovio As of October 2020, Operation Warp Speed had spent less than $1 billion...
Johnson & Johnson (Janssen Pharmaceutical), AstraZeneca-University of Oxford, Pfizer-BioNTech, Moderna, Merck, Vaxart, and Inovio. Funding from BARDA totaled...
candidate based on MedImmune's live, attenuated vaccine technology. Oct 2010 Inovio starts a phase I clinical trial of its H5N1 vaccine (VGX-3400X). Oct 2012...
Inc. Questions and Answers". FDA. April 12, 2019. "Hepatitis C vaccine by Inovio could be tested in humans by end of year". Philadelphia Business Journal...
Global Information
$7 Million(2020)[2]